Eli Lilly has forged a major partnership with Profluent to develop advanced gene-editing tools using artificial intelligence, aiming to address complex diseases through programmable protein design. The deal is valued at approximately $2.25 billion in potential milestones.
Profluent, an AI-first biotechnology firm supported by Jeff Bezos’s investment fund, utilizes large-scale foundation models to engineer functional proteins from scratch. The collaboration focuses on creating site-specific recombinases, a technology capable of large-scale DNA integration and replacement, which many experts view as a significant evolution beyond earlier gene-editing methods.
Under the terms of the agreement, Profluent will utilize its proprietary AI models to architect enzymes for specific genomic targets. Eli Lilly will hold the exclusive license to transition these designs into clinical stages and handle global distribution. Profluent is set to receive an upfront fee and is eligible for substantial payments as the candidates reach key development and commercial benchmarks.
This alliance marks another aggressive move by Eli Lilly to expand its genetic medicine pipeline, following a series of high-profile acquisitions and partnerships fueled by the company’s recent commercial successes.